Anne Ljungars

Anne Ljungars

Auto-generated profile, based on publicly available information

Anne Ljungars

Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in mAbs
Verified
Journal Article
Open access
MFMonica Fernandez-Quintero
Monica Fernandez-Quintero
ALAnne Ljungars
Anne Ljungars
FWFranz Waibl
Franz Waibl
VGVictor Greiff
Victor Greiff
JAJan Terje Andersen
Jan Terje Andersen
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properties that can be assessed early on for biologics. These include the influence of the source of the biologic, its biophysical and pharmacokinetic properties, and how well it can be expressed recombinantly. We furthermore present in silico, in vitro, and in vivo methods and techniques that can be exploited at different stages of the discovery process to identify molecules with liabilities and thereby facilitate the selection of the most optimal drug leads. Finally, we reflect on the most relevant developability parameters for injectable versus orally delivered biologics and provide an outlook toward what general trends are expected to rise in the development of biologics.

8 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLLine Ledsgaard
Line Ledsgaard
JWJack Wade
Jack Wade
TJTimothy P. Jenkins
Timothy P. Jenkins
KBKim Boddum
Kim Boddum
IOIrina Oganesyan
Irina Oganesyan
AKAneesh Karatt-Vellatt
Aneesh Karatt-Vellatt
Snakebite envenoming continues to claim many lives across the globe, necessitating the development of improved therapies. To this end, broadly-neutralizing human monoclonal antibodies may possess advantages over current plasma-derived antivenoms by offering superior safety and high neutralization capacity. Here, we report the establishment of a pipeline based on phage display technology for the discovery and optimization of high affinity broadly-neutralizing human monoclonal antibodies. This approach yielded a recombinant human antibody with superior broadly-neutralizing capacities in vitro and in vivo against different long-chain α-neurotoxins from elapid snakes. This antibody prevents lethality induced by Naja kaouthia whole venom at an unprecedented low molar ratio of one antibody per toxin and prolongs the survival of mice injected with Dendroaspis polylepis or Ophiophagus hannah whole venoms.

31 March 2025 in Nature Machine Intelligence
Verified
Journal Article
Open access
PDF file
KEKevin Eloff
Kevin Eloff
KKKonstantinos Kalogeropoulos
Konstantinos Kalogeropoulos
AMAmandla Mabona
Amandla Mabona
OMOliver Morell
Oliver Morell
RCRachel Catzel
Rachel Catzel
Timothy P. JenkinsTimothy P. Jenkins
Timothy P. Jenkins
Mass spectrometry-based proteomics focuses on identifying the peptide that generates a tandem mass spectrum. Traditional methods rely on protein databases but are often limited or inapplicable in certain contexts. De novo peptide sequencing, which assigns peptide sequences to spectra without prior information, is valuable for diverse biological applications; however, owing to a lack of accuracy, it remains challenging to apply. Here we introduce InstaNovo, a transformer model that translates fragment ion peaks into peptide sequences. We demonstrate that InstaNovo outperforms state-of-the-art methods and showcase its utility in several applications. We also introduce InstaNovo+, a diffusion model that improves performance through iterative refinement of predicted sequences. Using these models, we achieve improved therapeutic sequencing coverage, discover novel peptides and detect unreported organisms in diverse datasets, thereby expanding the scope and detection rate of proteomics searches. Our models unlock opportunities across domains such as direct protein sequencing, immunopeptidomics and exploration of the dark proteome.

29 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
SAShirin Ahmadi
Shirin Ahmadi
NBNick J. Burlet
Nick J. Burlet
MBMelisa Benard-Valle
Melisa Benard-Valle
AGAlid Guadarrama-Martínez
Alid Guadarrama-Martínez
SKSamuel Kerwin
Samuel Kerwin
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option 1 . Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species 2 . There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms 3 . Here we addressed this challenge by immunizing an alpaca and a llama with the venoms of 18 different snakes, including mambas, cobras and a rinkhals, constructing phage display libraries, and identifying high-affinity broadly neutralizing nanobodies. We combined eight of these nanobodies into a defined oligoclonal mixture, resulting in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin families or subfamilies. This antivenom effectively prevented venom-induced lethality in vivo across 17 African elapid snake species and markedly reduced venom-induced dermonecrosis for all tested cytotoxic venoms. The recombinant antivenom performed better than a currently used plasma-derived antivenom and therefore shows considerable promise for comprehensive, continent-wide protection against snakebites by all medically relevant African elapids.

13 December 2022 in GigaScience
Verified
Journal Article
Open access
PDF file
GNGiang Thi Tuyet Nguyen
Giang Thi Tuyet Nguyen
COCarol O'BRien
Carol O'BRien
YWYessica Wouters
Yessica Wouters
LSLorenzo Seneci
Lorenzo Seneci
AGAlex Gallissà-Calzado
Alex Gallissà-Calzado
ALAnne Ljungars
Anne Ljungars
Venomous snakes are important parts of the ecosystem, and their behavior and evolution have been shaped by their surrounding environments over the eons. This is reflected in their venoms, which are typically highly adapted for their biological niche, including their diet and defense mechanisms for deterring predators. Sub-Saharan Africa is rich in venomous snake species, of which many are dangerous to humans due to the high toxicity of their venoms and their ability to effectively deliver large amounts of venom into their victims via their bite. In this study, the venoms of 26 of sub-Saharan Africa's medically most relevant elapid and viper species were subjected to parallelized toxicovenomics analysis. The analysis included venom proteomics and in vitro functional characterization of whole venom toxicities, enabling a robust comparison of venom profiles between species. The data presented here corroborate previous studies and provide biochemical details for the clinical manifestations observed in envenomings by the 26 snake species. Moreover, two new venom proteomes (Naja anchietae and Echis leucogaster) are presented here for the first time. Combined, the presented data can help shine light on snake venom evolutionary trends and possibly be used to further improve or develop novel antivenoms.

21 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMelisa Benard-Valle
Melisa Benard-Valle
YWYessica Wouters
Yessica Wouters
ALAnne Ljungars
Anne Ljungars
GNGiang Thi Tuyet Nguyen
Giang Thi Tuyet Nguyen
SAShirin Ahmadi
Shirin Ahmadi
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Oligoclonal mixtures of broadly-neutralizing antibodies can neutralize complex compositions of similar and dissimilar antigens, making them versatile tools for the treatment of e.g., infectious diseases and animal envenomations. However, these biotherapeutics are complicated to develop due to their complex nature. In this work, we describe the application of various strategies for the discovery of cross-neutralizing nanobodies against key toxins in coral snake venoms using phage display technology. We prepare two oligoclonal mixtures of nanobodies and demonstrate their ability to neutralize the lethality induced by two North American coral snake venoms in mice, while individual nanobodies fail to do so. We thus show that an oligoclonal mixture of nanobodies can neutralize the lethality of venoms where the clinical syndrome is caused by more than one toxin family in a murine challenge model. The approaches described may find utility for the development of advanced biotherapeutics against snakebite envenomation and other pathologies where multi-epitope targeting is beneficial.